Active Not Recruiting PHASE2 INTERVENTIONAL 7-arm NCT05631262

SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors

A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors

Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Conditions Selected Subjects With Advanced Solid Tumors

Interventions Docetaxel SKB264

Updated 6 times since 2022 Last updated: Feb 11, 2026 Started: Nov 30, 2022 Primary completion: Dec 30, 2026 Completion: Dec 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Selected Subjects With Advanced Solid Tumors, this trial is ongoing. The trial is conducted by Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. and has accumulated 6 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE2
Mar 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Dec 2022 — Nov 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Nov 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Data source: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China